Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2015, Article ID 240750, 9 pages
http://dx.doi.org/10.1155/2015/240750
Clinical Study

Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study

1Analysis Group, Inc., Boston, MA 02199, USA
2Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
3Analysis Group, Inc., New York, NY 10020, USA

Received 19 February 2015; Revised 23 April 2015; Accepted 24 April 2015

Academic Editor: Zsuzsanna Kahán

Copyright © 2015 Nanxin Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. International Agency for Research on Cancer (IARC) and World Health Organization (WHO), Fact Sheets by Cancer—Breast Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012, GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012, International Agency for Research on Cancer (IARC), World Health Organization (WHO), 2014, http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
  2. SEER Cancer Statistics Factsheets: Breast Cancer, National Cancer Institute, 2014, http://seer.cancer.gov/statfacts/html/breast.html.
  3. A. M. Gonzalez-Angulo, F. Morales-Vasquez, and G. N. Hortobagyi, “Overview of resistance to systemic therapy in patients with breast cancer,” Advances in Experimental Medicine and Biology, vol. 608, pp. 1–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. D. Cossetti, S. K. Tyldesley, C. H. Speers, Y. Zheng, and K. A. Gelmon, “Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008,” Journal of Clinical Oncology, vol. 33, no. 1, pp. 65–73, 2015. View at Publisher · View at Google Scholar
  5. B. Kocic, S. Filipovic, B. Petrovic, D. Mijalkovic, N. Rancic, and A. Poultsidi, “Clinical and biological characteristics of breast cancer,” Journal of B.U.ON., vol. 15, no. 4, pp. 660–667, 2010. View at Google Scholar · View at Scopus
  6. Z. Mitri, T. Constantine, and R. O'Regan, “The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy,” Chemotherapy Research and Practice, vol. 2012, Article ID 743193, 7 pages, 2012. View at Publisher · View at Google Scholar
  7. K. A. Cadoo, M. N. Fornier, and P. G. Morris, “Biological subtypes of breast cancer: current concepts and implications for recurrence patterns,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 57, no. 4, pp. 312–321, 2013. View at Google Scholar · View at Scopus
  8. National Comprehensive Cancer Network(NCCN), NCCN: Clinical Practice Guidelines in Oncology—Breast cancer, NCCN Guidelines Version 3.2014, National Comprehensive Cancer Network(NCCN), 2014, http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
  9. E. Swallow, J. Zhang, D. Thomason, R. Tan, A. Kageleiry, and J. Signorovitch, “Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002–2012,” Current Medical Research and Opinion, vol. 30, no. 8, pp. 1537–1545, 2014. View at Publisher · View at Google Scholar
  10. A. R. Macalalad, Y. Hao, P. L. Lin et al., “Treatment patterns and duration in post-menopausal women with HR+/HER2− metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010),” Current Medical Research and Opinion, vol. 31, no. 2, pp. 263–273, 2015. View at Publisher · View at Google Scholar
  11. M. Stockler, N. R. C. Wilcken, D. Ghersi, and R. J. Simes, “Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer,” Cancer Treatment Reviews, vol. 26, no. 3, pp. 151–168, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Bergh, P.-E. Jönsson, B. Glimelius, and P. Nygren, “A systematic overview of chemotherapy effects in breast cancer,” Acta Oncologica, vol. 40, no. 2-3, pp. 253–281, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Baselga, M. Campone, M. Piccart et al., “Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer,” The New England Journal of Medicine, vol. 366, no. 6, pp. 520–529, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. D. A. Yardley, S. Noguchi, K. I. Pritchard et al., “Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis,” Advances in Therapy, vol. 30, no. 10, pp. 870–884, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. T. Beck, G. N. Hortobagyi, M. Campone et al., “Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2,” Breast Cancer Research and Treatment, vol. 143, no. 3, pp. 459–467, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Bachelot, C. Bourgier, C. Cropet et al., “Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study,” Journal of Clinical Oncology, vol. 30, no. 22, pp. 2718–2724, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Pouget, E. Planchat, C. Abrial et al., Everolimus Plus Hormonotherapy (HT) Induces Survival Gain in Late Metastatic Breast Cancer (MBC) after Progression: Could This Line Be Better Than a Late New Chemotherapy (CT) Line?Abstract # 401P, European Socity for Medical Oncologyity, 2014, https://www.webges.com/cslide/library/esmo/browse/search/oRS#9faC02xU.
  18. L. Krasnova, P. Vorobiev, and M. Holownia, “Clinical and economic analysis of effectiveness of everolimus in the treatment of HR+, HER2− advanced breast cancer in russia,” Value in Health, vol. 17, no. 7, article A635, 2014. View at Publisher · View at Google Scholar
  19. S. Cope, J. Zhang, B. Smiechowski, S. Saletan, J. P. Jansen, and P. Schmid, “Comparative efficacy of everolimus and exemestane versus chemotherapy for advanced breast cancer in terms of progression-free survival,” in Proceedings of the San Antonio Breast Cancer Symposium, abstract#P6-10-02, 2013, http://www.abstracts2view.com/sabcs13/viewp.php?nu=P6-10-03.
  20. S. Gao, B. Barber, V. Schabert, and C. Ferrufino, “Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe,” Current Medical Research and Opinion, vol. 28, no. 7, pp. 1111–1118, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. Novartis Pharmaceuticals, A Phase II Study of Everolimus in Combination with Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer (BOLERO-6), Clinicaltrials.gov NCT01783444, US National Institutes of Health, 2014, https://clinicaltrials.gov/ct2/show/NCT01783444.
  22. N. Wilcken, J. Hornbuckle, and D. Ghersi, “Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer,” The Cochrane Database of Systematic Reviews, no. 2, Article ID CD002747, 2003. View at Google Scholar · View at Scopus
  23. H. S. Rugo, K. I. Pritchard, M. Gnant et al., “Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2,” Annals of Oncology, vol. 25, no. 4, Article ID mdu009, pp. 808–815, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. K. I. Pritchard, H. A. Burris III, Y. Ito et al., “Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2,” Clinical Breast Cancer, vol. 13, no. 6, pp. 421–432, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Paplomata, A. Zelnak, and R. O'Regan, “Everolimus: side effect profile and management of toxicities in breast cancer,” Breast Cancer Research and Treatment, vol. 140, no. 3, pp. 453–462, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Campone, J. T. Beck, M. Gnant et al., “Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2 advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy,” Current Medical Research and Opinion, vol. 29, no. 11, pp. 1463–1473, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. D. L. Hershman and J. D. Wright, “Comparative effectiveness research in oncology methodology: observational data,” Journal of Clinical Oncology, vol. 30, no. 34, pp. 4215–4222, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Roche, H. Reddel, R. Martin et al., “Quality standards for real-world research. Focus on observational database studies of comparative effectiveness,” Annals of the American Thoracic Society, vol. 11, supplement 2, pp. S99–S104, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. L. P. Garrison Jr., P. J. Neumann, P. Erickson, D. Marshall, and C. D. Mullins, “Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report,” Value in Health, vol. 10, no. 5, pp. 326–335, 2007. View at Publisher · View at Google Scholar · View at Scopus